Monteverde & Associates PC, a top-ranked class action law firm, is investigating Bio-Techne Corporation's proposed sale to Merck KGaA. Shareholders are expected to receive $73 per share in cash under the deal. The firm encourages Bio-Techne shareholders to review the fairness of the offer and offers free legal consultation with no obligation. Monteverde & Associates has a strong track record of recovering money for shareholders in securities class actions.
Ademi LLP is investigating Bio-Techne's $11.3 billion sale to Merck for possible breaches of fiduciary duty by the board and unfair deal terms. Shareholders will get $73 per share, but insiders may gain extra benefits. The deal restricts competing bi...
Germany's Merck KGaA has agreed to acquire Bio-Techne for $11.3 billion, causing Bio-Techne shares to surge before the market opened. This acquisition highlights Merck's strategic expansion in the biotech sector. The deal is significant for investors...
